Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- Fuso Inks Sub-License Agreement for OTS102 with Otsuka
February 8, 2010
- Collect Clinically Significant PGx Evidence: Dr Uyama
February 8, 2010
- Kaken to Take Over Marketing of Synphase from Tsumura
February 8, 2010
- 4 Class C2 Med Devices Recommended for Reimbursement
February 8, 2010
- Astellas Transfers Yet Another Product to Choseido
February 8, 2010
- Bayer to Transfer Antsens to Horiba
February 8, 2010
- Criteria for FY2010 NHI Price Revision Approved by Chuikyo
February 8, 2010
- Loxoprofen-Based Switch OTC Drugs Approved
February 8, 2010
- Ensure Thorough Understanding of New Pricing System Among Healthcare Providers: Mr Shoda
February 8, 2010
- Remicade for Psoriasis: MTPC
February 1, 2010
- Bendamustine Added to NCCN GLs as First-Line Therapy: SymBio
February 1, 2010
- Antidepressant Cymbalta: Shionogi
February 1, 2010
- Anti-Flu Agent Rapiacta Included in NHI Price List
February 1, 2010
- Greater Importance Put on Surgery in Insurance Coverage
February 1, 2010
- Xalacom for Glaucoma: Pfizer
February 1, 2010
- Korosho to Ask Companies to Comment on the Need for Listed Unapproved Drugs
February 1, 2010
- Cymbalta to Drive Shionogi's Business in Mid-Term: Ms Sawada
February 1, 2010
- Sugammadex for Reversal of Neuromuscular Blockade: Schering-Plough
February 1, 2010
- New Premium to Allow Chuikyo to Interfere with Company Management : Prof. Tsutsumi
February 1, 2010
- Takeda to More Actively Develop Business in Emerging Markets: President Hasegawa
February 1, 2010
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…